Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bvf Partners LP Il Insider Profile
326 Followers
Bvf Partners LP Il, See Explanation of Responses at ChemoCentryx, holds 87.91K shares in 4D Molecular Therapeutics (Ticker: FDMT), holds 176.69K shares in Third Harmonic Bio, Inc. (Ticker: THRD), holds 1.29M shares in MoonLake Immunotherapeutics (Ticker: MLTX).
Bvf Partners LP Il ChemoCentryx (CCXI)See Explanation of Responses
ChemoCentryx (CCXI)
See Explanation of Responses
Ranked #22 out of 99,335 Corporate Insiders
Profitable Transactions
89 out of 141 Profitable Transactions
Average Return
+51.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Bvf Partners LP Il holds in companies
Most Profitable Insider Trade
Stock:
Five Prime Therapeutics
(FPRX)
(FPRX)
Rating:Informative Buy
Date:Nov 26, 2019 - Nov 26, 2020
Return:+467.90%
The most profitable trade made by Bvf Partners LP Il
Bvf Partners LP Il's Trading History
ChemoCentryx
Nov 05, 2015
―
Uninformative Sell
―
$177.51M
CTI BioPharma
Jun 28, 2023
―
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
―
$2.37M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
$132.21K
Xoma
Jan 09, 2023
Director, See Remarks, Ten Percent Owner
Informative Buy
420.63K
$115.64M
GlycoMimetics
Nov 06, 2020
Ten Percent Owner
Informative Buy
3.29M
$201.74K
Concert Pharma
Jun 12, 2019
―
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
―
$1.33M
Immune Design
Dec 04, 2018
―
Informative Sell
1.65M
$2.17M
Pieris Pharmaceuticals
Sep 10, 2019
Ten Percent Owner
Informative Sell
224.50K
$5.01M
Five Prime Therapeutics
Nov 13, 2020
―
Informative Sell
149.20M
$3.09M
Calithera Bio
May 26, 2020
―
Informative Sell
13.70M
$12.01K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$336.84M
Merus
Oct 08, 2021
Ten Percent Owner
Informative Sell
31.22M
$10.32M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$6.20M
Principia Biopharma
―
―
―
―
Kymera Therapeutics
Nov 06, 2023
Director, See Remarks and Footnotes
Informative Buy
5.30M
$219.94M
Olema Pharmaceuticals
Sep 14, 2023
Director, Ten Percent Owner
Informative Buy
14.82M
$70.02M
Eledon Pharmaceuticals
May 13, 2024
Ten Percent Owner
Uninformative Buy
―
$25.30M
CytomX Therapeutics
―
See Explanation of Responses
―
$4.74M
Rain Oncology
Jan 29, 2024
―
Uninformative Sell
―
$0.00
Repare Therapeutics
Nov 17, 2023
Ten Percent Owner
Informative Buy
6.24M
$1.63M
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
―
$784.05K
Third Harmonic Bio, Inc.
Oct 31, 2024
See Explanation of Responses
Informative Sell
14.30M
$2.02M
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
―
$155.74M
MoonLake Immunotherapeutics
Oct 08, 2024
Director, Ten Percent Owner
Informative Sell
100.00M
$66.78M
POINT Biopharma Global
Dec 20, 2023
―
Informative Sell
213.66M
$0.00
4D Molecular Therapeutics
Nov 13, 2024
See Explanation of Responses
Uninformative Sell
―
$702.41K
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$28.26M
Cascadian Therapeutics
Dec 22, 2015
―
Informative Buy
―
$207.39M
Dynavax
Sep 11, 2009
Ten Percent Owner
Informative Sell
3.35M
$211.55M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.13B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.57B
Epirus Biopharma
Dec 24, 2009
―
Informative Sell
2.54M
$13.66M
Array Biopharma
Jul 10, 2014
―
Uninformative Sell
2.25M
$596.76M
Amag Pharmaceuticals
―
―
―
$14.15M
Arqule
Jun 01, 2018
―
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$190.52M
Tobira Therapeutics
Mar 25, 2014
―
Uninformative Sell
―
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$24.40M
Repros
―
―
―
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$15.17M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$2.34M
Astex Pharmaceuticals
―
―
―
―
Medicinova
―
Ten Percent Owner
―
$0.00
NPS Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock
You May Also Like
Bvf Partners LP Il insider profile FAQ
What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 63%.
What is the average return per transaction made by Bvf Partners LP Il?
The average return per transaction made by Bvf Partners LP Il is 51.50%.
What stocks does Bvf Partners LP Il hold?
Bvf Partners LP Il holds: CCXI, CTIC, XENE, INFIQ, XOMA, GLYC, CNCE, SNDX, IMDZ, PIRS, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, PNT, FDMT, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTN, ASTX, MNOV, NPSP stocks.
What was Bvf Partners LP Il’s latest transaction?
Bvf Partners LP Il latest transaction was an Uninformative Sell of ―.
What was Bvf Partners LP Il's most profitable transaction?
Bvf Partners LP Il’s most profitable transaction was an Informative Buy of FPRX stock on November 26, 2019. The return on the trade was 467.90%.
What is Bvf Partners LP Il's role in ChemoCentryx?
Bvf Partners LP Il's role in ChemoCentryx is See Explanation of Responses.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.